HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

AbstractSTUDY OBJECTIVES:
To determine, in patients with type 2 diabetes mellitus, whether an association exists between thiazolidinedione therapy or other diabetes therapies and hospital admission for heart failure.
DESIGN:
Retrospective case-control study.
DATA SOURCE:
Oregon Medicaid claims database.
PATIENTS:
A total of 288 case patients and 1652 control patients.
MEASUREMENTS AND MAIN RESULTS:
Case patients were defined as any patients hospitalized for heart failure, controls as any patients with a hospital claim for a condition other than heart failure. Controls were matched by age and sex in a 6:1 ratio. Exposure to a thiazolidinedione or other antihyperglycemic drug was assessed 60 days before the first hospitalization. This was used to construct an odds ratio of exposure in case patients compared with controls using a multivariate logistic regression model and controlling for potential confounders. Charlson comorbidity index scores and frequency of diabetes-related office visits were significantly higher for case patients than for controls. The unadjusted and adjusted odds ratios for exposure to a thiazolidinedione were 1.71 (95% confidence interval [CI] 1.24-2.36) and 1.37 (95% CI 0.98-1.92), respectively. The unadjusted and adjusted odds ratios for exposure to insulin in patients hospitalized for heart failure were 1.68 (95% CI 1.27-2.22) and 1.25 (95% CI 0.92-1.69), respectively. The unadjusted and adjusted odds ratios for exposure to a combination of insulin and a thiazolidinedione in case patients were 1.81 (95% CI 1.14-2.86) and 1.35 (95% CI 0.84-2.18), respectively. No association with hospitalization for heart failure was found for patients exposed to a sulfonylurea, metformin, or alpha-glucosidase inhibitor.
CONCLUSION:
This study showed a likely association between thiazolidinedione therapy and hospitalization for heart failure within 60 days of the prescription date. A similar trend occurred with insulin therapy alone and with the combination of thiazolidinedione and insulin, but not with other oral antihyperglycemics. When thiazolidinediones are prescribed, careful consideration should be given to patients with known heart failure. In addition, all patients should be educated regarding heart failure and monitored for signs and symptoms.
AuthorsDaniel M Hartung, Daniel R Touchette, Nanette C Bultemeier, Dean G Haxby
JournalPharmacotherapy (Pharmacotherapy) Vol. 25 Issue 10 Pg. 1329-36 (Oct 2005) ISSN: 0277-0008 [Print] United States
PMID16185176 (Publication Type: Journal Article)
Chemical References
  • Chromans
  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone
  • Troglitazone
  • Pioglitazone
Topics
  • Adult
  • Aged
  • Case-Control Studies
  • Chromans (adverse effects)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Female
  • Heart Failure (chemically induced)
  • Hospitalization
  • Humans
  • Hypoglycemic Agents (adverse effects)
  • Male
  • Medicaid
  • Middle Aged
  • Pioglitazone
  • Retrospective Studies
  • Risk
  • Rosiglitazone
  • Thiazolidinediones (adverse effects)
  • Troglitazone

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: